Gastric cancer
Conditions
Interventions
experimental group:docetaxel plus capecitabine
control group:oxalipatin plus capecitabine
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written (signed) informed consent.; 2. Without liver, peritoneal, retroperitoneal lymph node and other distant metastasis; 3. Pathological diagnosed gastric adenocarcinoma, recieving gastrectomy with D2 lymph node dissection, R0 resetion; 4. ECGO 0-1; 5. Female/male, 18-75year; 6. Expected survival > 3 months; 7. Laboratory detection in 7 days before inclusion should meet the following criteria: a. Adequate hematological function: Leukocyte >= 4.0 *10^9/L,Neutrophil count >= 1.5 * 10^9/L, Platelets >= 100 * 10^9/L and Hemoglobin >= 90g/L; b. Adequate liver function: Total bilirubin = 60 ml/min. d. Adequate coagulation function: INR/PT <= 1.5 x ULN, aPTT <= 1.5 * ULN. 8. Good compliance.
Exclusion criteria
Exclusion criteria: 1. Patients with active malignant tumor in recent 2 years, except the tumor studied in this research or cured locally tumor like resected basal cell or squamous cell skin cancer, superficial bladder cancer,cervical or breast carcinoma in situ; 2. Intolerance of the oral drugs; 3. Patients with the history of chemotherapy, radiotherapy and immunotherapy; 4. Allergic to the investigatory drugs; 5. Female patients should not be pregnant or breast feeding; 6. Any other disease or condition of clinical significance that the investigator believes may affect protocol compliance, or affect subjects' signing of informed consent (ICF), or ineligibility to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free suvival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;aderse event; | — |
Countries
China
Contacts
Public ContactYuanfang Li
Sun Yat-Sen University Cancer Center
Outcome results
None listed